<DOC>
	<DOCNO>NCT02675439</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , pharmacokinetics , pharmacodynamics antitumor activity MIW815 ( ADU-S100 ) administer via intratumoral injection .</brief_summary>
	<brief_title>Study Safety Efficacy MIW815 ( ADU-S100 ) Patients With Advanced/Metastatic Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>ECOG â‰¤ 1 Willing undergo tumor biopsy inject distal lesion Must two biopsy accessible lesion : * one lesion must 10 mm &lt; 100 mm long diameter , accessible repeat intratumoral ( IT ) injection accessible baseline ontreatment biopsy . second ( distal ) lesion must accessible baseline ontreatment biopsy must distinct injected lesion . tumor encase major vascular structure ( i.e. , carotid artery tumor close vital organ ) , consider appropriate Patients require local palliative measure XRT surgery Symptomatic untreated leptomeningeal disease . Presence symptomatic central nervous system ( CNS ) metastases Impaired cardiac function clinically significant cardiac disease Active autoimmune disease document history autoimmune disease , except vitiligo resolve childhood asthma/atopy . Active infection require systemic antibiotic therapy . Known history Human Immunodeficiency Virus ( HIV ) infection . Active EpsteinBarr virus ( EBV ) , HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) Malignant disease , treat study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>